A CASE OF AUTOIMMUNE HEPATITIS WITH GRAVES' DISEASE TREATED BY PROPYLTHIOURACIL

被引:0
|
作者
Sato, Ikuko [1 ]
Tsunekawa, Taku [1 ]
Shinohara, Yuri [1 ]
Nishio, Yuichiro [1 ]
Shimizu, Yuko [2 ]
Suzuki, Yasuhiko [3 ]
Yoshioka, Shuko [1 ]
机构
[1] Tosei Gen Hosp, Dept Endocrinol & Diabet, Seto 4898642, Japan
[2] Tosei Gen Hosp, Dept Gastroenterol, Seto 4898642, Japan
[3] Tosei Gen Hosp, Dept Pathol, Seto 4898642, Japan
来源
NAGOYA JOURNAL OF MEDICAL SCIENCE | 2011年 / 73卷 / 3-4期
关键词
Graves' disease; Propylthiouracil; Autoimmune hepatitis;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A 58-year-old woman was referred to our hospital because of liver dysfunction. Her serum levels of AST (619 IU/l) and ALT (603 IU/l) had increased. Histological findings in the liver biopsy were compatible to autoimmune hepatitis (AIH), and the diagnosis of AIH was confirmed by the diagnostic criteria. She was admitted to a nearby hospital 3 years ago, and diagnosed with Graves' disease. She received methimazole (MMI) at first, which was discontinued due to liver injury in one month, then propylthiouracil (PTU) was administered. One year later, transaminase increased and was decreased by stopping PTU administration. PTU was restarted after her transaminase decreased, but a recurrence of hepatotoxicity was observed, and she was referred to our hospital. Oral prednisolone decreased liver function immediately. In this case, PTU-induced liver injury was suspected as a possible trigger of AIH. While PTU remains a commonly used drug in the treatment of hyperthyroidism, severe liver injury is reported in some cases. If liver injury is observed in patients treated with PTU, rechallenge is not recommended in order to avoid severe hepatotoxicity.
引用
收藏
页码:205 / 209
页数:5
相关论文
共 50 条
  • [21] Management of fetal hyperthyroidism caused by persistent autoimmune antibodies in a case of previously treated maternal Graves' disease
    Karri, Susmita Reddy
    Roy, Priya Susan
    Nandi, Nirjhar
    Shenoy, Vasant
    Watson, David
    OBSTETRIC MEDICINE, 2024, 17 (02) : 108 - 111
  • [23] CELLULAR AUTOIMMUNE INVOLVEMENT IN GRAVES-DISEASE TREATED BY ANTITHYROID DRUGS
    ALLANNIC, H
    GENETET, N
    EDAN, G
    MERDRIGNAC, G
    SIMON, M
    GENETET, B
    PATHOLOGIE BIOLOGIE, 1987, 35 (10): : 1333 - 1338
  • [24] CELLULAR AUTOIMMUNE INVOLVEMENT IN GRAVES-DISEASE TREATED BY ANTITHYROID DRUGS
    ALLANNIC, H
    GENETET, N
    EDAN, G
    MERDRIGNAC, G
    SIMON, M
    GENETET, B
    SEMAINE DES HOPITAUX, 1988, 64 (42): : 2702 - 2707
  • [25] Therapy with propylthiouracil for T3-predominant neonatal Graves' disease: a case report
    Hamajima, Emi
    Noda, Masahiro
    Nai, Emina
    Akiyama, Satoka
    Ikuta, Yoji
    Obana, Natsuko
    Kawaguchi, Takahiro
    Hayashi, Kenta
    Oba, Kunihiro
    Yoshida, Tomohiro
    Katori, Tatsuo
    Kokaji, Masayuki
    CLINICAL PEDIATRIC ENDOCRINOLOGY, 2018, 27 (03) : 171 - 178
  • [26] RECTAL ADMINISTRATION OF PROPYLTHIOURACIL IN THE TREATMENT OF GRAVES-DISEASE
    WALTER, RM
    BARTLE, WR
    AMERICAN JOURNAL OF MEDICINE, 1990, 88 (01): : 69 - 70
  • [27] Acute autoimmune myocarditis secondary to Graves' disease: a case report
    Demoulin, R.
    Poyet, R.
    Parsai, C.
    Capilla, E.
    Rohel, G.
    Pons, F.
    Jego, C.
    Cellarier, G. R.
    REVUE DE MEDECINE INTERNE, 2020, 41 (03): : 206 - 209
  • [29] MYELOPEROXIDASE AND PROTEINASE-3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY TITERS IN GRAVES' DISEASE PATIENTS TREATED WITH PROPYLTHIOURACIL
    Baser, H.
    Tuzun, D.
    Balkan, F.
    Dirikoc, A.
    Lam, F. Sag
    Ersoy, R.
    Cakir, B.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2013, 9 (04) : 543 - 550